# 2026年2月16日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. 脂质体纳米局域化实现 I 型光动力转换，用于协同癌症光热-免疫治疗

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41691507)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41691507
**DOI：** 10.1002/advs.202515013

### 第一部分 原文与翻译

**英文原标题：** Liposomal Nanoconfinement Enables Type I Photodynamic Conversion for Synergistic Cancer Photothermal-Immunotherapy.

> **英文摘要：**
> Type-I photodynamic therapy (PDT) agents offer a promising approach for treating hypoxic tumors. However, previous reports mainly focused on thermodynamic modulation through molecular engineering to block the Type-II energy transfer pathway. Herein, we present a facile strategy to realize the conversion of Type II to Type I PDT by integrating liposomal confinement and electron/hydrogen transfer pathway. A multifunctional nanoplatform, RhM-R837@Lip was developed, which facilitates an efficient shift from Type II to Type I for hemicyanine-based photosensitizer (PS) by suppressing singlet oxygen (O) generation while promoting superoxide anion (O ) and hydroxyl radical (•OH). Lipids serve as electron donors, facilitating electron transfer to form PS radical anions. Additionally, liposomal nanoconfinement acts as a photothermal nanoreactor, achieving a photothermal conversion efficiency as high as 56.1%. Co-encapsulation of immunoadjuvant R837 stimulates systemic immune responses, synergistically enhancing tumor eradication. This radical-switching behavior, driven by liposomal nanoconfinement and the donor-π-acceptor (D-π-A) structural configuration, modulates electron transfer pathways to favor Type-I photoreactions. The RhM-R837@Lip nanoplatform provides a versatile, integrated strategy to overcome hypoxic tumor microenvironments, improving PDT and photocatalytic performance, and effectively inhibits tumor metastasis.

> **中文摘要：**
> I 型光动力疗法（PDT）试剂为治疗缺氧肿瘤提供了一种极具前景的方法。然而，先前的研究主要集中在通过分子工程进行热力学调控以阻断 II 型能量转移路径。在此，我们提出了一种简便的策略，通过整合脂质体局域化和电子/氢转移路径，实现从 II 型到 I 型 PDT 的转变。我们开发了一种多功能纳米平台 RhM-R837@Lip，该平台通过抑制单线态氧（O2）的产生，同时促进超氧阴离子（O2•-）和羟基自由基（•OH）的生成，促进了半花菁类光敏剂（PS）从 II 型向 I 型的有效转变。脂质作为电子供体，促进电子转移以形成光敏剂自由基阴离子。此外，脂质体纳米局域化充当光热纳米反应器，实现了高达 56.1% 的光热转换效率。免疫佐剂 R837 的共同封装激发了全身免疫反应，协同增强了肿瘤清除效果。这种由脂质体纳米局域化和供体-π-受体（D-π-A）结构配置驱动的自由基转换行为，通过调节电子转移路径使反应倾向于 I 型光反应。RhM-R837@Lip 纳米平台提供了一种通用的集成策略来克服缺氧肿瘤微环境，提高了 PDT 和光催化性能，并有效抑制了肿瘤转移。

### 第二部分 AI 大师评价

本文通过脂质体纳米局域化策略，成功实现了半花菁类光敏剂从 II 型向 I 型光动力反应的路径切换。研究创新性地利用脂质作为电子供体，在缺氧条件下通过 D-π-A 结构诱导自由基产生，并结合高达 56.1% 的极高光热转换效率。通过整合免疫佐剂 R837，该系统构建了“光动力-光热-免疫”三位一体的协同治疗模式，不仅有效克服了肿瘤缺氧耐受性，还展现了优异的抗肿瘤转移潜力，为开发高性能、抗缺氧的集成化纳米诊疗平台提供了新的分子工程范式。

---

## 2. 选择性靶向尖端内皮细胞作为肿瘤血管生成的治疗策略

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41691491)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41691491
**DOI：** 10.1002/advs.202512975

### 第一部分 原文与翻译

**英文原标题：** Selective Targeting of Tip Endothelial Cells as a Therapeutic Strategy for Tumor Angiogenesis.

> **英文摘要：**
> Tip endothelial cells (EC), the leading edge of angiogenic sprouts, are essential for pathological neo-vascularization but remain difficult to target due to the lack of specific druggable markers. Here, we identify Doppel as a selective and druggable regulator of endothelial tip cell function. Doppel expression enhances EC selection, directional migration, and regulates tip-stalk cell dynamics by spatially controlling VEGFR2/Dll4/Src pathway. Genetic ablation of PRND (Doppel) reduces tip cell formation without affecting the stalk cells (ECs) number in tumors, indicating its selective role in ECs. Importantly, depletion of ECs using the first-in-class monoclonal antibodies against a highly conserved WQF-motif of Doppel robustly decreased the growth of tumors by selectively downregulating VEGFR2+ ECs but not ECs. These findings position Doppel as a tumor EC-specific, druggable target that may offer a new avenue to enhance and refine anti-angiogenic therapies in cancer treatment.

> **中文摘要：**
> 尖端内皮细胞（EC）作为血管生成芽的前缘，对病理性新血管形成至关重要，但由于缺乏特异性的成药标志物，目前仍难以靶向。在此，我们鉴定出 Doppel 是内皮尖端细胞功能的一种选择性且可成药的调节因子。Doppel 的表达通过空间调控 VEGFR2/Dll4/Src 通路，增强了内皮细胞的选择、定向迁移，并调节了尖端-柄部细胞的动力学平衡。遗传敲除 PRND（Doppel）可减少肿瘤中尖端细胞的形成，而不影响柄部细胞（内皮细胞）的数量，表明其在尖端内皮细胞中具有选择性作用。重要的是，使用针对 Doppel 高度保守 WQF 基序的首创单克隆抗体清除尖端内皮细胞，通过选择性下调 VEGFR2+ 内皮细胞而非普通内皮细胞，显著抑制了肿瘤生长。这些发现将 Doppel 定位为一种肿瘤尖端内皮细胞特异性的、可成药的靶点，可能为增强和完善癌症治疗中的抗血管生成疗法提供新途径。

### 第二部分 AI 大师评价

本研究深入探讨了肿瘤血管生成中尖端内皮细胞（tip ECs）的精准干预策略，成功鉴定出关键调节因子 Doppel。研究揭示了 Doppel 通过 VEGFR2/Dll4/Src 通路调控血管芽分支的分子机制，并通过遗传缺失实验验证了其对尖端细胞的选择性作用。最具临床转化意义的是，研究者开发了针对 Doppel 保守基序的首创单克隆抗体，证明了其在抑制肿瘤生长方面的显著疗效且不影响正常内皮细胞。该成果为开发高特异性、低毒副作用的新一代抗血管生成药物提供了坚实的实验依据和新颖的靶点选择。

---

## 3. 非小细胞肺癌肿瘤边界处 DSG2+ 癌症干细胞与 FAP+ 肌成纤维细胞共定位，决定免疫治疗疗效

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41691490)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41691490
**DOI：** 10.1002/advs.202514543

### 第一部分 原文与翻译

**英文原标题：** DSG2+ Cancer Stem Cells Co-Located With FAP+ Myofibroblasts in the Tumor Boundary That Determines the Efficacy of Immunotherapy in Non-Small Cell Lung Cancer.

> **英文摘要：**
> Lung cancer remains a leading cause of cancer-related mortality owing to its aggressiveness and pronounced heterogeneity. Cancer stem cells (CSCs) have been implicated in tumor progression and therapeutic resistance; however, their transcriptional programs and spatial organization in non-small cell lung cancer (NSCLC) are not fully characterized. Here, we integrated single-cell RNA sequencing with spatial transcriptomics to systematically define CSC-associated phenotype in NSCLC. Weighted gene co-expression network analysis identified a 127-gene CSC signature enriched for stemness-related pathways, with DSG2 emerging as a dominant marker. Elevated DSG2 expression was associated with chemotherapy resistance and predicted response to EGFR tyrosine kinase inhibitors based on independent clinical proteomic datasets. Spatial mapping revealed preferential enrichment of DSG2+CSCs at tumor margins, where they co-localized with FAP+myofibroblasts (myCAFs). Multiplex immunofluorescence demonstrated that FAP+myCAFs expressed MMP9 and MMP12, consistent with a microenvironment supportive of epithelial-mesenchymal transition and CSC maintenance. Functional co-culture assays showed that myCAFs enhanced CSC-associated phenotypes in DSG2^high tumor cells in an MMP-dependent manner. Collectively, these findings delineate a spatially organized DSG2+CSC-myCAF niche that contributes to therapeutic resistance in NSCLC.

> **中文摘要：**
> 由于肺癌具有高度侵袭性和显著的异质性，它仍然是癌症相关死亡的主要原因。癌症干细胞（CSCs）被认为与肿瘤进展和治疗耐药性有关；然而，它们在非小细胞肺癌（NSCLC）中的转录程序和空间组织尚未得到充分表征。在本研究中，我们整合了单细胞 RNA 测序与空间转录组学技术，系统地定义了 NSCLC 中 CSC 相关的表型。加权基因共表达网络分析确定了一个包含 127 个基因的 CSC 特征集，该特征集在干性相关通路中显著富集，其中 DSG2 脱颖而出成为主导标志物。基于独立的临床蛋白质组数据集，DSG2 的高表达与化疗耐药性相关，并能预测患者对 EGFR 酪氨酸激酶抑制剂的反应。空间制图显示，DSG2+ CSCs 优先富集在肿瘤边缘，并在该处与 FAP+ 肌成纤维细胞（myCAFs）共定位。多重免疫荧光实验证实，FAP+ myCAFs 表达 MMP9 和 MMP12，这与支持上皮-间质转化和 CSC 维持的微环境一致。功能性共培养实验表明，myCAFs 以 MMP 依赖的方式增强了 DSG2 高表达肿瘤细胞中的 CSC 相关表型。总的来说，这些发现描绘了一个空间组织的 DSG2+ CSC-myCAF 龛位（niche），该结构促进了 NSCLC 的治疗耐药。

### 第二部分 AI 大师评价

本研究通过整合单细胞转录组与空间转录组技术，首次在空间维度上界定了非小细胞肺癌肿瘤边缘的 DSG2+ CSCs 与 FAP+ myCAFs 形成的共定位结构。研究不仅鉴定出 DSG2 作为关键的干性与疗效预测标志物，还阐明了 myCAFs 通过分泌 MMP 维持肿瘤干性的具体机制。这一发现为理解肿瘤微环境如何塑造干细胞龛位提供了重要证据，并为克服 NSCLC 治疗耐药提供了潜在的干预靶点，具有较高的临床转化指导价值。

---

## 4. UBE2T驱动的p53降解重塑糖酵解，进而协调乳酸化介导的癌相关成纤维细胞激活与胰腺癌中的细胞外基质沉积

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41691486)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41691486
**DOI：** 10.1002/advs.202514933

### 第一部分 原文与翻译

**英文原标题：** UBE2T-Driven p53 Degradation Rewires Glycolysis to Orchestrate Lactylation-Mediated CAFs Activation and ECM Deposition in Pancreatic Cancer.

> **英文摘要：**
> Although glycolysis is a metabolic hallmark of pancreatic ductal adenocarcinoma (PDAC), it remains unclear whether the excessive lactate produced regulates CAF lactylation to promote extracellular matrix (ECM) deposition. The multi-omics and spontaneous model findings indicate that lactate accumulation in the tumor microenvironment (TME) promotes histone H3 lysine 18 lactylation (H3K18la) and activation of cancer-associated fibroblasts (CAFs), leading to both ECM densification and impaired immunotherapy efficacy in PDAC. Mechanistically, ubiquitin-conjugating enzyme E2T (UBE2T) acts as an initiating factor that promotes p53 positive feedback degradation through modulation of ribosome biogenesis, thereby enhancing lactate metabolic crosstalk via glycolytic reprogramming. Genetic ablation or pharmacological inhibition of UBE2T using the selective inhibitor pentagalloylglucose (PGG) disrupts lactate metabolic crosstalk, suppresses stromal deposition, and promotes intratumoral CD8 T cells infiltration. Furthermore, the combination of PGG and anti-PD-1 therapy exhibits synergistic effects and survival benefits in spontaneous PDAC mice and immune-reconstituted patient-derived xenografts. Collectively, these findings reveal that UBE2T drives p53 positive feedback degradation to enhance glycolysis of PDAC, leading to excessive lactate production, which promotes H3K18la in CAFs and subsequent ECM deposition. Targeting UBE2T represents a potential strategy to improve the efficacy of immunotherapy in PDAC.

> **中文摘要：**
> 尽管糖酵解是胰腺导管腺癌（PDAC）的一种代谢特征，但目前尚不清楚产生的过量乳酸是否通过调节癌相关成纤维细胞（CAF）乳酸化来促进细胞外基质（ECM）沉积。多组学和自发模型的研究结果表明，肿瘤微环境（TME）中的乳酸积累促进了组蛋白 H3 第 18 位赖氨酸乳酸化（H3K18la）和 CAF 的激活，导致 PDAC 中 ECM 致密化并损害了免疫治疗的疗效。在机制上，泛素结合酶 E2T (UBE2T) 作为启动因子，通过调节核糖体生物合成促进 p53 的正反馈降解，从而通过糖酵解重编程增强乳酸代谢串扰。使用选择性抑制剂五倍子酸（PGG）对 UBE2T 进行基因消减或药理学抑制，可以破坏乳酸代谢串扰，抑制间质沉积，并促进肿瘤内 CD8+ T 细胞浸润。此外，PGG 与抗 PD-1 疗法的联合应用在自发 PDAC 小鼠和免疫重建的人源肿瘤异种移植模型中显示出协同效应和生存获益。总的来说，这些发现揭示了 UBE2T 驱动 p53 的正反馈降解以增强 PDAC 的糖酵解，导致乳酸产生过多，进而促进 CAF 中的 H3K18la 及其随后的 ECM 沉积。靶向 UBE2T 代表了提高 PDAC 免疫治疗疗效的一种潜在策略。

### 第二部分 AI 大师评价

本研究深入探讨了胰腺癌中 UBE2T/p53 轴如何通过代谢重编程重构肿瘤微环境。作者通过精密的机制研究揭示了乳酸诱导的组蛋白乳酸化（H3K18la）是驱动 CAF 激活和细胞外基质沉积的关键环节。研究不仅在理论上阐明了糖酵解与基质致密化之间的代谢互作，还通过小分子抑制剂 PGG 展示了靶向该通路联合免疫治疗的显著临床转化潜力，为改善 PDAC 免疫治疗耐药提供了新靶点。

---

## 5. USP7和RNF40介导的拮抗性泛素化转换协同调控KDM6A稳态以许可冠状病毒易感性

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41691482)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41691482
**DOI：** 10.1002/advs.202518058

### 第一部分 原文与翻译

**英文原标题：** Antagonistic Ubiquitin Switching by USP7 and RNF40 Orchestrates KDM6A Homeostasis to License Coronavirus Susceptibility.

> **英文摘要：**
> Lysine demethylase 6A (KDM6A) is a critical epigenetic regulator implicated in development, cancer, and viral infection. Although KDM6A enhances coronavirus entry by modulating viral receptor expression, the mechanisms governing its protein stability remain unknown. Here, we show that ubiquitin-specific protease 7 (USP7) promotes diverse coronavirus infection, including SARS-CoV, SARS-CoV-2, MERS-CoV, and MHV, and represents a broad-spectrum anti-coronavirus target. Genetic and pharmacological inhibition of USP7 attenuates the expression of coronavirus receptors ACE2, DPP4, and Ceacam1, thereby impeding viral entry. Mechanistically, USP7 deubiquitinates KDM6A by removing K48-linked polyubiquitin chains to prevent its proteasomal degradation. Conversely, the E3 ubiquitin ligase RNF40 catalyzes K6- and K11-linked ubiquitination of KDM6A, which serves as a signal for recognition by TAX1BP1 for autophagic degradation, to restrict diverse coronavirus infection. Pharmacological inhibition of USP7 with FT671 and XL177A reduces KDM6A stability and viral receptor expression, and confers resistance to MERS-CoV, SARS-CoV, and all major SARS-CoV-2 variants of concern, including those resistant to remdesivir in primary human airway and intestinal epithelial cells. In mice, FT671 treatment was well tolerated, reduced Ceacam1 expression, and protected against MHV-A59 infection. Collectively, our findings unveil an antagonistic ubiquitin-mediated regulatory circuit that controls KDM6A stability, viral receptor levels, and coronavirus infection.

> **中文摘要：**
> 赖氨酸去甲基化酶 6A (KDM6A) 是一种关键的表观遗传调节因子，涉及发育、癌症和病毒感染。虽然 KDM6A 通过调节病毒受体表达来增强冠状病毒的进入，但控制其蛋白质稳定性的机制仍不清楚。在此，我们发现泛素特异性蛋白酶 7 (USP7) 促进多种冠状病毒的感染，包括 SARS-CoV、SARS-CoV-2、MERS-CoV 和 MHV，并可作为一种广谱抗冠状病毒靶点。遗传学和药理学抑制 USP7 可降低冠状病毒受体 ACE2、DPP4 和 Ceacam1 的表达，从而阻碍病毒进入。从机制上讲，USP7 通过去除 K48 连接的多泛素链使 KDM6A 去泛素化，从而防止其被蛋白酶体降解。相反，E3 泛素连接酶 RNF40 催化 KDM6A 的 K6 和 K11 连接泛素化，这作为 TAX1BP1 识别进行自噬降解的信号，从而限制多种冠状病毒的感染。使用 FT671 和 XL177A 对 USP7 进行药理学抑制可降低 KDM6A 的稳定性和病毒受体表达，并对 MERS-CoV、SARS-CoV 以及所有主要的 SARS-CoV-2 关注变异株（包括原代人呼吸道和肠上皮细胞中对瑞德西韦耐药的变异株）产生抗性。在小鼠中，FT671 治疗耐受性良好，降低了 Ceacam1 表达，并对 MHV-A59 感染具有保护作用。总之，我们的研究结果揭示了一个由拮抗性泛素介导的调节回路，该回路控制 KDM6A 的稳定性、病毒受体水平和冠状病毒感染。

### 第二部分 AI 大师评价

该研究深入探讨了表观遗传调节因子KDM6A在冠状病毒感染中的关键作用，揭示了由去泛素化酶USP7和泛素连接酶RNF40构成的拮抗性调控回路。研究证明，USP7通过维持KDM6A稳态促进病毒受体表达，而RNF40则介导其自噬降解，这一机制在多种冠状病毒中具有普适性。通过药理学手段抑制USP7在体外和体内模型中均表现出显著的广谱抗病毒潜力，不仅能应对主要SARS-CoV-2变异株，还对瑞德西韦耐药株有效，为冠状病毒防治提供了全新的宿主靶向治疗思路。

---

## 6. SiCmiR Atlas：单细胞 miRNA 图谱揭示人类癌症中的核心 miRNA 及网络特征

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41691474)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41691474
**DOI：** 10.1002/advs.202514446

### 第一部分 原文与翻译

**英文原标题：** SiCmiR Atlas: Single-Cell miRNA Landscape Reveals Hub-miRNA and Network Signatures in Human Cancers.

> **英文摘要：**
> MicroRNAs (miRNAs) are pivotal post‑transcriptional regulators whose single‑cell behavior has remained largely inaccessible due to technical barriers in single-cell small‑RNA profiling. We present SiCmiR, a two‑layer neural network that predicts miRNA expression profiles from only 977 LINCS L1000 landmark genes, thereby reducing sensitivity to dropout in single-cell RNA-seq (scRNA-seq) data. Proof‑of‑concept analyses illustrate how SiCmiR can uncover candidate hub‑miRNAs in bulk-seq cell lines and hepatocellular carcinoma, scRNA-seq pancreatic ductal carcinoma, and ACTH‑secreting pituitary adenoma and extracellular vesicle (EV)‑mediated crosstalk in glioblastoma. Trained on 6,462 TCGA paired miRNA-mRNA samples, SiCmiR attains state‑of‑the‑art accuracy on cancers and generalizes to unseen cancer types and drug perturbations. We next construct SiCmiR‑Atlas, containing 362 public datasets, 9.36 million cells, and 726 cell types, which is the first dedicated database of single‑cell mature miRNA expression, providing interactive visualization, biomarker identification, and cell‑type‑resolved miRNA-target networks. SiCmiR transforms bulk‑derived statistical power into a single‑cell view of miRNA biology and provides a community resource for biomarker discovery. SiCmiR Atlas is available at https://awi.cuhk.edu.cn/∼SiCmiR/.

> **中文摘要：**
> MicroRNAs (miRNAs) 是关键的转录后调节因子，由于单细胞小 RNA 测序的技术壁垒，其单细胞水平的行为在很大程度上仍难以获取。我们提出了 SiCmiR，这是一个两层神经网络，仅通过 977 个 LINCS L1000 地标基因即可预测 miRNA 表达谱，从而降低了单细胞 RNA 测序 (scRNA-seq) 数据对基因丢失 (dropout) 现象的敏感性。概念验证分析阐明了 SiCmiR 如何在体转录组测序 (bulk-seq) 细胞系和肝细胞癌、单细胞测序 (scRNA-seq) 胰腺导管癌、促肾上腺皮质激素 (ACTH) 分泌型垂体腺瘤以及胶质母细胞瘤中细胞外囊泡 (EV) 介导的细胞间通讯中，揭示候选核心 miRNA。SiCmiR 基于 6,462 个 TCGA 配对 miRNA-mRNA 样本进行训练，在癌症预测上达到了最先进的准确度，并可推广至未见的癌症类型和药物扰动。随后，我们构建了 SiCmiR-Atlas，包含 362 个公共数据集、936 万个细胞和 726 种细胞类型，这是首个专门的单细胞成熟 miRNA 表达数据库，提供交互式可视化、生物标志物识别以及细胞类型解析的 miRNA 靶向网络。SiCmiR 将源自大块组织的统计效力转化为 miRNA 生物学的单细胞视角，并为生物标志物的发现提供了社区资源。SiCmiR Atlas 可在 https://awi.cuhk.edu.cn/~SiCmiR/ 获取。

### 第二部分 AI 大师评价

该研究通过开发 SiCmiR 神经网络模型，巧妙地解决了单细胞层面小 RNA 测序难度大、数据稀疏的瓶颈问题。利用少量的地标基因预测全基因组范围的 miRNA 表达，不仅提高了分析的鲁棒性，还通过构建庞大的 SiCmiR-Atlas 填补了领域内单细胞 miRNA 专用数据库的空白。该工具在多种癌症模型和细胞通讯研究中展现了卓越的泛化能力和生物学解释力，是单细胞转录组学与表观遗传学结合的重要里程碑。

---

## 7. 高内涵SRS成像揭示CAR-T治疗下卵巢癌胆固醇代谢的改变

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41691468)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41691468
**DOI：** 10.1002/advs.202518334

### 第一部分 原文与翻译

**英文原标题：** High-Content SRS Imaging Unveils Altered Cholesterol Metabolism in Ovarian Cancers Under CAR-T Treatment.

> **英文摘要：**
> Ovarian cancer is one of the most lethal gynecological cancers worldwide and has one of the highest recurrence rates. Recently developed Chimeric Antigen Receptor (CAR) -T cell therapy has shown potent clinical efficacy against hematological malignancies. However, solid tumors, including ovarian cancer, possess several mechanisms that hinder T cell activity, and metabolic alteration of cancer cells has been shown to contribute to resistance to immune cell attack against solid tumors. Here, we explore the metabolic response of ovarian cancer cells to CAR-T cell attack using label-free high-content hyperspectral stimulated Raman scattering (hSRS) imaging. Utilizing visible hSRS imaging with much improved spatial resolution, we find an altered cholesterol metabolism, featured by increased storage of cholesteryl ester in lipid droplets and free cholesterol, in ovarian cancer cells that survive the CAR-T treatment. Administration of Avasimibe, an inhibitor of cholesteryl esterification, further enhances CAR-T cytotoxicity. Our study shows the promise of implementing metabolic modulation to facilitate CAR-T cell treatment of solid tumors.

> **中文摘要：**
> 卵巢癌是全球最致命的妇科癌症之一，且复发率最高。近期开发的嵌合抗原受体（CAR）-T细胞疗法在血液系统恶性肿瘤中展现出强大的临床疗效。然而，包括卵巢癌在内的实体瘤具有多种阻碍T细胞活性的机制，且研究表明癌细胞的代谢改变有助于抵抗针对实体瘤的免疫细胞攻击。在本研究中，我们利用无标记高内涵超光谱受激拉曼散射（hSRS）成像技术探索了卵巢癌细胞对CAR-T细胞攻击的代谢反应。利用空间分辨率显著提高的可见光hSRS成像，我们发现在CAR-T治疗后存活的卵巢癌细胞中，胆固醇代谢发生了改变，其特征是脂滴中胆固醇酯的储存增加以及游离胆固醇水平升高。使用胆固醇酯化抑制剂Avasimibe可进一步增强CAR-T的细胞毒性。我们的研究展示了实施代谢调节以促进CAR-T细胞治疗实体瘤的前景。

### 第二部分 AI 大师评价

该研究利用先进的可见光超光谱受激拉曼散射（hSRS）成像技术，以前所未有的空间分辨率揭示了卵巢癌在CAR-T压力下的代谢逃逸特征。研究明确了胆固醇代谢改变（尤其是胆固醇酯在脂滴中的蓄积）是癌细胞抵抗免疫攻击的关键机制，并证实了联用胆固醇酯化抑制剂Avasimibe可显著提升CAR-T疗效。这一发现不仅深化了对实体瘤免疫耐药性的代谢理解，也为开发“代谢-免疫”联合治疗方案提供了坚实的实验依据。

---

## 8. 铂类药物介导的自然杀伤细胞活化增强 HR/HER2 乳腺癌的免疫治疗

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41691453)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41691453
**DOI：** 10.1002/advs.202518978

### 第一部分 原文与翻译

**英文原标题：** NK Cell Activation by Platinum Boosts Immunotherapy in HR/HER2 Breast Cancer.

> **英文摘要：**
> Immunotherapy revolutionizes cancer therapeutics but shows limited efficacy in hormone receptor-positive (HR)/human epidermal growth factor receptor 2-negative (HER2) breast cancer. By leveraging large-scale multi-omics and single-cell RNA sequencing (scRNA-seq), we characterize the tumor microenvironment of HR/HER2 breast cancer, revealing that an abundance of activated natural killer (NK) cells correlates with favorable anti-PD-(L)1 responses. Our preclinical models demonstrate that immunotherapy enhances NK cell cytotoxicity and immunomodulatory functions, thereby impeding tumor growth. Furthermore, drug screening of cell lines and patient-derived tumors reveals that platinum enhances NK cell cytotoxicity, potentially via the NF-κB pathway, creating synergy with immunotherapy. Consistent with these findings, a clinical cohort analysis shows an increased proportion of activated NK cells in tumors following platinum-based chemotherapy. Collectively, our study establishes the critical role of NK cells in mediating immunotherapy response in HR/HER2 breast cancer and uncovers a novel mechanism whereby platinum agents augment immunotherapeutic efficacy, offering a promising combination strategy.

> **中文摘要：**
> 免疫疗法彻底改变了癌症治疗方法，但在激素受体阳性（HR）/人表皮生长因子受体 2 阴性（HER2）乳腺癌中疗效有限。通过利用大规模多组学和单细胞 RNA 测序（scRNA-seq），我们对 HR/HER2 乳腺癌的肿瘤微环境进行了表征，揭示了活化的自然杀伤（NK）细胞的丰富程度与良好的抗 PD-(L)1 反应相关。我们的临床前模型证明，免疫疗法可增强 NK 细胞的细胞毒性和免疫调节功能，从而阻碍肿瘤生长。此外，对细胞系和患者来源肿瘤的药物筛选显示，铂类药物可增强 NK 细胞的细胞毒性，其机制可能涉及 NF-κB 通路，从而与免疫疗法产生协同作用。与这些发现一致的是，一项临床队列分析显示，在接受铂类化疗后，肿瘤中活化 NK 细胞的比例有所增加。总之，本研究确立了 NK 细胞在介导 HR/HER2 乳腺癌免疫治疗反应中的关键作用，并揭示了铂类药物增强免疫治疗疗效的新机制，提供了一种具有前景的联合治疗策略。

### 第二部分 AI 大师评价

该研究利用多组学和单细胞测序技术，深入揭示了 NK 细胞在 HR/HER2 乳腺癌免疫治疗中的核心地位。研究不仅证明了 NK 细胞浸润与抗 PD-(L)1 疗效呈正相关，还通过药物筛选发现了铂类药物通过 NF-κB 通路增强 NK 细胞毒性的新机制。这种铂类诱导的免疫微环境重塑为临床解决 HR+/HER2- 乳腺癌免疫治疗耐药问题提供了重要的科学依据和联合用药方案。

---

## 9. 经肿瘤纯度校正的 DNA 甲基化定义的肺腺癌亚型的多组学评估

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41691315)
**期刊：** Genome medicine
**PMID：** 41691315
**DOI：** 10.1186/s13073-026-01609-x

### 第一部分 原文与翻译

**英文原标题：** Multiomics assessment of lung adenocarcinoma subtypes defined through tumor purity-adjusted DNA methylation.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要。

### 第二部分 AI 大师评价

本研究通过对肿瘤纯度进行校正，利用DNA甲基化特征重新定义了肺腺癌的分子亚型，并进行了多组学层面的深入评估。该方法的核心创新在于有效排除了非肿瘤细胞成分对甲基化信号的干扰，从而能更真实地反映肿瘤实质的表观遗传特征。研究揭示了不同亚型在多组学维度的显著差异，为肺腺癌的精准临床分型和个性化治疗提供了重要的理论依据和数据支持。

---

## 10. FBXW7 突变通过激活 ETV6-GLUT1 轴重编程葡萄糖代谢

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41691251)
**期刊：** Molecular cancer
**PMID：** 41691251
**DOI：** 10.1186/s12943-026-02605-w

### 第一部分 原文与翻译

**英文原标题：** FBXW7 mutations reprogram glucose metabolism by activating the ETV6-GLUT1 axis.

> **英文摘要：**
> The progression of endometrial cancer (EC) involves substantial metabolic reprogramming, frequently driven by mutations in tumor suppressors and oncogenes. In this study, we identify a previously unrecognized pathway through which FBXW7 mutations rewire glucose metabolism in EC cells. Specifically, we demonstrate that loss-of-function mutations in FBXW7 disrupt the SCF E3 ubiquitin ligase complex, resulting in the stabilization of the transcription factor ETV6 by preventing its ubiquitin-mediated degradation. Accumulated ETV6 subsequently enhances the transcriptional activation of glucose transporter 1 (GLUT1), elevating its expression and localization to the plasma membrane. This increased GLUT1 expression significantly enhances glucose uptake, fueling both aerobic glycolysis and oxidative phosphorylation, which collectively accelerate EC cell proliferation and tumor growth. Importantly, targeting GLUT1 pharmacologically partially reverses the proliferative advantage conferred by ETV6 overexpression, highlighting a promising therapeutic vulnerability. Our findings establish the FBXW7-ETV6-GLUT1 regulatory axis as a critical driver of metabolic adaptation and tumor progression, offering potential strategies for targeted therapy in FBXW7-mutant EC.

> **中文摘要：**
> 子宫内膜癌（EC）的进展涉及显著的代谢重编程，这通常由抑癌基因和癌基因的突变驱动。在本研究中，我们确定了一条此前未被认识的途径，FBXW7 突变通过该途径重新连接 EC 细胞中的葡萄糖代谢。具体而言，我们证明 FBXW7 的功能缺失突变破坏了 SCF E3 泛素连接酶复合物，从而通过防止转录因子 ETV6 发生泛素介导的降解使其稳定。积累的 ETV6 随后增强了葡萄糖转运蛋白 1（GLUT1）的转录激活，提升了其表达量及在质膜上的定位。这种 GLUT1 表达的增加显著增强了葡萄糖摄取，为有氧糖酵解和氧化磷酸化提供了动力，从而共同加速了 EC 细胞的增殖和肿瘤生长。重要的是，通过药物靶向 GLUT1 可部分逆转 ETV6 过表达带来的增殖优势，凸显了一个极具前景的治疗脆弱点。我们的发现确立了 FBXW7-ETV6-GLUT1 调节轴是代谢适应和肿瘤进展的关键驱动因素，为 FBXW7 突变型 EC 的靶向治疗提供了潜在策略。

### 第二部分 AI 大师评价

本研究揭示了子宫内膜癌中 FBXW7 突变驱动代谢重编程的新机制，即通过破坏 SCF 复合物介导的泛素化降解来稳定转录因子 ETV6，进而上调 GLUT1 表达。研究深入探讨了蛋白质周转与细胞能量代谢之间的分子联系，阐明了肿瘤细胞如何通过协同增强糖酵解和氧化磷酸化来维持生长优势。该发现不仅界定了 FBXW7-ETV6-GLUT1 这一关键致癌信号轴，还为 FBXW7 突变型患者提供了靶向 GLUT1 进行代谢干预的理论依据，具有较强的临床转化潜力。

---

## 11. Sortilin通过限制EGFR转导功能展现类抑癌活性

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41691060)
**期刊：** Oncogene
**PMID：** 41691060
**DOI：** 10.1038/s41388-026-03680-5

### 第一部分 原文与翻译

**英文原标题：** Sortilin exhibits tumor suppressor-like activity by limiting EGFR transduction function.

> **英文摘要：**
> Lung cancer is the leading cause of cancer deaths worldwide and remains one of the most difficult to cure. Tyrosine kinase receptors, such as the epidermal growth factor receptor (EGFR), are often aberrantly activated by gene mutation and drive tumor growth. Monotherapy with tyrosine kinase inhibitors targeting EGFR has shown initial efficacy, but their benefits tend to decline over time. EGFR acts as a transcription factor promoting the expression of oncogenic drivers, which, in turn, cooperate with canonical EGFR mutations to induce therapeutic resistance. This study reports that sortilin, a crucial regulator of cytoplasmic EGFR, attenuates its transducing function. Genome-wide chromatin binding assays revealed that sortilin interacts with gene regulatory elements occupied by EGFR. These results suggest a model in which sortilin exhibits potential tumor suppressor-like activity by concurrently binding to regulatory elements of cMYC. Sortilin expression in lung adenocarcinoma may be predictive of the efficacy of anti-EGFR therapies.

> **中文摘要：**
> 肺癌是全球癌症死亡的主要原因，也是最难治愈的癌症之一。酪氨酸激酶受体，如表皮生长因子受体（EGFR），常因基因突变而发生异常激活并驱动肿瘤生长。针对EGFR的酪氨酸激酶抑制剂单药治疗已显示出初步疗效，但其获益往往随时间推移而下降。EGFR作为转录因子促进癌基因驱动因子的表达，进而与典型的EGFR突变协同诱导治疗耐药性。本研究报道了细胞质EGFR的关键调节因子sortilin能够减弱其转导功能。全基因组染色质结合分析显示，sortilin与EGFR占据的基因调节元件相互作用。这些结果提出了一个模型，即sortilin通过同时结合cMYC的调节元件，展现出潜在的抑癌样活性。肺腺癌中sortilin的表达可能对抗EGFR疗法的疗效具有预测价值。

### 第二部分 AI 大师评价

本研究揭示了Sortilin作为肺腺癌抑癌因子的新机制，发现其能通过干预胞质EGFR向核内转录功能的转导来抑制肿瘤进展。研究通过全基因组染色质结合分析，创新性地证明了Sortilin与EGFR协同作用于cMYC等关键致癌元件的调节过程。这一发现不仅深化了对EGFR非经典信号通路的理解，还为克服EGFR-TKI耐药提供了新的潜在生物标志物和治疗靶点。

---

## 12. BRD4协调GM-CSF表达与分泌的代谢-表观遗传调控，驱动三阴性乳腺癌中PD-L1⁺巨噬细胞介导的免疫逃逸

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41691059)
**期刊：** Oncogene
**PMID：** 41691059
**DOI：** 10.1038/s41388-026-03681-4

### 第一部分 原文与翻译

**英文原标题：** BRD4 orchestrates the metabolic-epigenetic regulation of GM-CSF expression and secretion to drive PD-L1⁺ macrophage-mediated immune evasion in triple-negative breast cancer.

> **英文摘要：**
> Immune checkpoint blockade targeting the PD-1/PD-L1 axis shows promise in triple-negative breast cancer (TNBC), yet durable responses are limited by immune escape. Here, we identified tumor-derived bromodomain-containing protein 4 (BRD4) as a critical mediator of tumor-associated macrophage (TAMs)-driven immune evasion in TNBC. Using syngeneic TNBC mouse models, we found that BRD4 promotes PD-L1 expression on TAMs by increasing GM-CSF production from tumor cells. Mechanistically, BRD4 binds to the GM-CSF promoter enriched with H4K8 lactylation (H4K8La) and H3K27 acetylation (H3K27Ac). BRD4 further sustains pyruvate and lactate pools via upregulation of PKM2, thereby amplifying H4K8La and H3K27Ac on the basis of modifications at the GM-CSF locus. Functionally, exogenous GM-CSF supplementation rescued impaired tumor growth and defective activation of TAMs caused by BRD4 inhibition, establishing a direct BRD4-GM-CSF-TAMs regulatory axis. Therapeutically, combined treatment with the BRD4 inhibitor JQ1 or the first bromodomain (BD1) selective inhibitor MS402 and an anti-GM-CSF antibody markedly suppressed TNBC progression and converted the tumor immune microenvironment from "cold" to "hot". In conclusion, our study reveals a previously unrecognized metabolic-epigenetic mechanism through which BRD4 drives GM-CSF-dependent TAMs activation and immune evasion in TNBC. Targeting BRD4 in combination with GM-CSF blockade represents a promising therapeutic strategy to overcome immune resistance in this aggressive breast cancer subtype.

> **中文摘要：**
> 针对PD-1/PD-L1轴的免疫检查点阻断疗法在三阴性乳腺癌（TNBC）中展现出前景，但其持久反应受到免疫逃逸的限制。在此，我们鉴定出肿瘤来源的含溴结构域蛋白4（BRD4）是TNBC中肿瘤相关巨噬细胞（TAMs）驱动免疫逃逸的关键介质。利用同基因TNBC小鼠模型，我们发现BRD4通过增加肿瘤细胞产生的GM-CSF，促进TAMs上的PD-L1表达。机制上，BRD4结合到富含H4K8乳酸化（H4K8La）和H3K27乙酰化（H3K27Ac）修饰的GM-CSF启动子区域。BRD4通过上调PKM2进一步维持丙酮酸和乳酸池，从而在GM-CSF位点原有修饰的基础上放大了H4K8La和H3K27Ac水平。功能上，外源性GM-CSF补充挽救了由BRD4抑制引起的肿瘤生长受阻和TAMs激活缺陷，从而建立了直接的BRD4-GM-CSF-TAMs调节轴。治疗方面，联合使用BRD4抑制剂JQ1或第一溴结构域（BD1）选择性抑制剂MS402以及抗GM-CSF抗体，可显著抑制TNBC进展，并将肿瘤免疫微环境从“冷”转变为“热”。总之，我们的研究揭示了一种此前未被认识的代谢-表观遗传机制，BRD4通过该机制驱动GM-CSF依赖性的TAMs激活和TNBC中的免疫逃逸。靶向BRD4联合GM-CSF阻断代表了克服这种侵袭性乳腺癌亚型免疫耐药的一种有前景的治疗策略。

### 第二部分 AI 大师评价

本研究揭示了BRD4通过“代谢-表观遗传”双重路径调控三阴性乳腺癌（TNBC）免疫微环境的新机制。研究发现BRD4不仅作为转录因子结合GM-CSF启动子，还通过上调PKM2增强糖酵解代谢产物，进而通过H4K8乳酸化和H3K27乙酰化修饰协同促进GM-CSF分泌，驱动PD-L1⁺巨噬细胞介导的免疫逃逸。该发现为TNBC的免疫治疗提供了新靶点，特别是BRD4抑制剂与GM-CSF抗体的联合方案在将“冷肿瘤”转化为“热肿瘤”方面表现出显著的临床转化潜力。

---

## 13. 基于铁死亡纳米疗法改善免疫抑制微环境下的结直肠癌相关成纤维细胞

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41690961)
**期刊：** Nature communications
**PMID：** 41690961
**DOI：** 10.1038/s41467-026-69462-5

### 第一部分 原文与翻译

**英文原标题：** Amelioration of colorectal cancer-associated fibroblasts in immunosuppressive microenvironment by ferroptosis-based nanotherapy.

> **英文摘要：**
> Most colorectal cancers (CRCs) are insensitive to cancer immunotherapy due to the tumor-promoting activities and immunosuppressive effects of cancer-associated fibroblasts (CAFs), which profoundly drive cancer progression. Here, we provide a treatment strategy targeting CAFs to remodel the structural and immune tumor microenvironment of CRC based on magnetic nanoparticles. These nanoparticles not only induce the enhanced ferroptosis of CAFs through the synergistic effect of iron and copper ions but also ameliorate the immunosuppressive tumor microenvironment, simultaneously breaking down physical obstructions and activating the immune system. Mechanistically, these nanoparticles regulate the intrinsic signaling pathways of CAFs and alter chemokine secretion to improve the maturation of dendritic cells and the activation and function of CD8 T cells, eventually resulting in boosting the immune response to inhibit CRC growth. Moreover, we verify the effectiveness of this strategy in the patient-derived xenograft and organoid models, further illustrating its universality and promising clinical translational potential. Collectively, we show that our magnetic nanoparticles targeting CAFs can reprogram the tumor microenvironment of CRC by breaking down physical barriers and alleviating immunosuppression, offering promising avenues for the therapeutic strategy in clinical CRC management.

> **中文摘要：**
> 由于癌相关成纤维细胞（CAFs）具有促癌活性和免疫抑制效应，深刻驱动着癌症进展，大多数结直肠癌（CRCs）对癌症免疫治疗不敏感。在此，我们提供了一种基于磁性纳米颗粒的治疗策略，旨在靶向CAFs以重塑结直肠癌的结构和免疫肿瘤微环境。这些纳米颗粒不仅通过铁离子和铜离子的协同作用诱导CAFs发生增强的铁死亡，还改善了免疫抑制性的肿瘤微环境，同时打破了物理障碍并激活了免疫系统。从机制上讲，这些纳米颗粒调节了CAFs的内在信号通路并改变了趋化因子的分泌，从而促进了树突状细胞的成熟以及CD8 T细胞的激活与功能，最终增强了免疫反应以抑制结直肠癌的生长。此外，我们在患者来源的异种移植模型和类器官模型中验证了该策略的有效性，进一步说明了其普适性和巨大的临床转化潜力。总而言之，我们表明靶向CAFs的磁性纳米颗粒能够通过打破物理屏障和减轻免疫抑制来重编程结直肠癌的肿瘤微环境，为临床结直肠癌治疗策略提供了有前景的途径。

### 第二部分 AI 大师评价

该研究针对结直肠癌中因CAFs介导的物理屏障和免疫抑制导致的治疗耐药难题，创新性地提出了一种基于铁死亡的磁性纳米颗粒疗法。通过铁与铜离子的协同作用靶向诱导CAFs铁死亡，成功重塑了肿瘤微环境，增强了CD8+ T细胞的抗肿瘤免疫。实验在类器官及PDX模型中验证了其卓越的普适性与转化前景，为结直肠癌的精准免疫治疗提供了新的纳米医学范式。

---

## 14. HECT连接酶HECTD3的结构与机制

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41690955)
**期刊：** Nature communications
**PMID：** 41690955
**DOI：** 10.1038/s41467-026-69520-y

### 第一部分 原文与翻译

**英文原标题：** Structure and mechanism of the HECT ligase HECTD3.

> **英文摘要：**
> HECT E3 ligases regulate many cellular processes, yet how they recognise their substrates and synthesise specific types of poly-ubiquitin chains is still incompletely understood. HECTD3, a member of the "other HECT" family, is implicated in the regulation of inflammation, apoptosis, and infection and highly expressed in several cancers. These functions are largely attributed to its ligase activity and modification of diverse substrates with different types of ubiquitin chains. We present a detailed analysis of the ligase activity of HECTD3, including its ubiquitin linkage preferences, oligomeric state and substrate ubiquitination. Using cryo-EM, we provide the full-length structures of HECTD3 in both apo and ubiquitin-loaded forms, revealing key insights into its domain organisation, including discovery of a distinct fold of the N-terminal region, and mechanistic features. Some of these are shared with other HECT ligases, while others are unique to HECTD3 and contribute to differences in its catalytic mechanisms and functional diversity.

> **中文摘要：**
> HECT E3泛素连接酶调节许多细胞过程，然而它们如何识别底物并合成特定类型的多泛素链仍未被完全理解。HECTD3是“其他HECT”家族的成员，参与炎症、凋亡和感染的调节，并在多种癌症中高表达。这些功能很大程度上归功于其连接酶活性以及对不同底物进行不同类型泛素链的修饰。我们对HECTD3的连接酶活性进行了详细分析，包括其泛素连接偏好、寡聚状态和底物泛素化。利用冷冻电镜（cryo-EM），我们提供了HECTD3在脱辅基态和载泛素态下的全长结构，揭示了其结构域组织的深刻见解，包括发现N端区域的一种独特折叠以及相关的机制特征。其中一些特征与其他HECT连接酶共有，而其他特征则是HECTD3所特有的，并促成了其催化机制和功能多样性的差异。

### 第二部分 AI 大师评价

本文通过冷冻电镜技术深入解析了HECTD3这一重要E3泛素连接酶的全长结构，填补了“其他HECT”家族成员在结构生物学研究上的空白。研究详细揭示了HECTD3在脱辅基状态和泛素结合状态下的构象变化，特别是其N端独特折叠的发现，为理解其底物识别和泛素链合成提供了关键的分子基础。这些发现不仅阐明了HECTD3独特的催化机制，也为其作为癌症和炎症治疗靶点的潜力提供了关键的结构生物学依据。

---

## 15. 配体依赖性 Wnt 信号通过微环境中的透明质酸表达促进胃癌转移

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41690948)
**期刊：** Nature communications
**PMID：** 41690948
**DOI：** 10.1038/s41467-026-69470-5

### 第一部分 原文与翻译

**英文原标题：** Ligand-dependent Wnt signaling promotes gastric cancer metastasis through hyaluronan expression in microenvironment.

> **英文摘要：**
> The majority of gastric cancer cells proliferate in a Wnt ligand-dependent manner. To investigate this, we generated mice harboring Kras, Tgfbr2, and Trp53 (KTP) as well as with the same mutations plus Wnt1 expression (WKTP) in gastric mucosa. While KTP mice develop gastric metaplasia, WKTP mice develop dysplastic tumors, highlighting the role of ligand-dependent Wnt signaling in primary tumorigenesis. Organoids derived from WKTP mice form liver metastases following splenic transplantation, whereas KTP organoids do not. Notably, Apc disruption fails to induce metastasis of KTP cells, suggesting that stromal Wnt signaling promotes metastasis. Mechanistically, tumor-derived Wnt ligands cooperate with TGFβ signaling to induce Has2 expression in cancer-associated fibroblasts (CAFs), leading to hyaluronan accumulation in the metastatic microenvironment. Strikingly, hyaluronidase expression in WKTP cells significantly suppresses liver metastasis. Here we show the critical role of ligand-dependent Wnt signaling and Has2-mediated hyaluronan deposition in metastasis, offering potential therapeutic strategy against gastric cancer metastasis.

> **中文摘要：**
> 大多数胃癌细胞以 Wnt 配体依赖的方式增殖。为了研究这一点，我们构建了在胃黏膜中携带 Kras、Tgfbr2 和 Trp53 (KTP) 突变以及携带相同突变并表达 Wnt1 (WKTP) 的小鼠。虽然 KTP 小鼠会发生胃化生，但 WKTP 小鼠会形成异型增生肿瘤，这突显了配体依赖性 Wnt 信号在原发性肿瘤发生中的作用。源自 WKTP 小鼠的类器官在脾移植后会形成肝转移，而 KTP 类器官则不会。值得注意的是，Apc 基因的破坏未能诱导 KTP 细胞发生转移，这表明基质 Wnt 信号促进了转移。从机制上讲，肿瘤衍生的 Wnt 配体与 TGFβ 信号协同作用，诱导癌相关成纤维细胞 (CAFs) 中 Has2 的表达，导致转移微环境中透明质酸的积累。引人注目的是，在 WKTP 细胞中表达透明质酸酶可显著抑制肝转移。本研究展示了配体依赖性 Wnt 信号和 Has2 介导的透明质酸沉积在转移中的关键作用，为针对胃癌转移提供了潜在的治疗策略。

### 第二部分 AI 大师评价

本研究利用精密的 KTP/WKTP 基因修饰小鼠及类器官模型，深入探讨了配体依赖性 Wnt 信号在胃癌恶性进展中的核心机制。研究不仅明确了该信号通路在原发肿瘤发生中的驱动作用，更创新性地揭示了肿瘤源性 Wnt 信号与 TGFβ 协同作用，通过调控癌相关成纤维细胞（CAF）的 Has2 表达诱导透明质酸沉积，从而重塑转移微环境。该发现突破了以往对 Wnt 信号仅作为胞内通路的认知，强调了其在肿瘤-间质相互作用中的关键地位，为针对透明质酸微环境防治胃癌转移提供了坚实的实验依据和潜在靶点。

---

## 16. 髓系巨噬细胞中溶酶体TMEM175缺失通过炎性体和交叉呈递途径发挥抗肿瘤免疫作用

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41690940)
**期刊：** Nature communications
**PMID：** 41690940
**DOI：** 10.1038/s41467-026-69546-2

### 第一部分 原文与翻译

**英文原标题：** Deficiency of lysosomal TMEM175 in myeloid macrophages exerts anti-tumor immunity via inflammasome and cross-presentation pathway.

> **英文摘要：**
> Discovering more targets is of great importance for developing alternative interventions for tumor therapy. The roles of transmembrane protein 175 (TMEM175) in neurodegeneration diseases have been reported, however its functions in tumor immune surveillance are not known. We show that TMEM175 conditional knockout in macrophages inhibits the tumor growth and metastasis through promoting the anti-tumor immunity in the tumor microenvironment (TME), including elevated M1-like polarization, reduced M2-like polarization, and facilitated recruitment and activation of T cells and nature killer cells (NKs). The anti-tumor immunity is abrogated by caspase-1 inhibitor VX-765, anti-IL-1β, and anti-IL-18. Tmem175 bone marrow-derived macrophages (BMDMs) show enhanced tumor antigen cross-presentation that is further strengthened by IL-1β and IL-18. NLRP3 is robustly elicited in Tmem175 BMDMs by the tumor cell debris through lysosomal permeabilization and cathepsin B leakage. Finally, Tmem175 mice are more responsive to anti-PD-1. Our works implies TMEM175 to be a potential target for immunotherapy.

> **中文摘要：**
> 发现更多靶点对于开发肿瘤治疗的替代干预措施具有重要意义。跨膜蛋白175 (TMEM175) 在神经退行性疾病中的作用已有报道，但其在肿瘤免疫监视中的功能尚不清楚。我们证明，巨噬细胞中 TMEM175 的条件性敲除通过促进肿瘤微环境 (TME) 中的抗肿瘤免疫，从而抑制肿瘤生长和转移，具体包括提升 M1 样极化、减少 M2 样极化，并促进 T 细胞和自然杀伤细胞 (NKs) 的募集与活化。这种抗肿瘤免疫作用可被 caspase-1 抑制剂 VX-765、抗 IL-1β 和抗 IL-18 所阻断。Tmem175 缺失的小鼠骨髓来源巨噬细胞 (BMDMs) 表现出增强的肿瘤抗原交叉呈递，且这种增强作用在 IL-1β 和 IL-18 存在下进一步加强。肿瘤细胞碎片通过溶酶体通透化和组织蛋白酶 B 泄漏，在 Tmem175 缺失的 BMDMs 中强烈诱导了 NLRP3。最后，Tmem175 敲除小鼠对抗 PD-1 治疗更为敏感。我们的研究表明 TMEM175 是免疫治疗的一个潜在靶点。

### 第二部分 AI 大师评价

本研究揭示了溶酶体离子通道蛋白TMEM175在肿瘤免疫中的关键调控作用，将其功能从神经退行性疾病领域扩展到了肿瘤免疫学。通过巨噬细胞特异性敲除模型，作者证实了TMEM175缺失能通过诱发溶酶体通透化激活NLRP3炎性体，进而驱动抗肿瘤因子的分泌和抗原交叉呈递。该发现不仅阐明了溶酶体稳态失调如何重塑肿瘤微环境，还为提高PD-1抑制剂疗效提供了新的联合治疗靶点，具有较强的创新性和转化价值。

---

## 17. 脑源性神经营养因子及其衍生的十二肽在急性肺损伤中作为 Toll 样受体 4 拮抗剂发挥作用

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41690930)
**期刊：** Nature communications
**PMID：** 41690930
**DOI：** 10.1038/s41467-026-69541-7

### 第一部分 原文与翻译

**英文原标题：** Brain-derived neurotrophic factor and the derived dodecapeptide function as Toll-like receptor 4 antagonists in acute lung injury.

> **英文摘要：**
> The neurotrophic factor (NTF) family has recently expanded its role beyond neurological conditions, but its involvement in acute inflammatory lung diseases remains largely unclear. Using well-established acute lung injury (ALI) and sepsis models, we demonstrate that brain-derived neurotrophic factor (BDNF), a key NTF, is impaired in pulmonary epithelial cells and negatively correlates with the inflammatory response. Raising the BDNF level alleviates inflammatory lung injury, but these effects are absent in macrophage-deleted mice. Both in vivo and in vitro results show BDNF inhibits macrophage inflammation, and further proteomics analysis identifies macrophage TLR4 as a receptor that BDNF antagonizes via direct binding. The BDNF fragment (aa 104-115) is critical for BDNF-TLR4 interaction, and the corresponding synthetic BDNF-derived dodecapeptide (BDP-12) retains TLR4-antagonistic and anti-inflammatory effects both in vitro and in vivo, without pro-proliferative side effects. In conclusion, our findings reveal that epithelial-derived BDNF prevents macrophage inflammation by directly targeting TLR4 and highlights BDP-12 as a potential therapeutic agent for acute inflammatory diseases.

> **中文摘要：**
> 神经营养因子（NTF）家族近期将其作用扩展到了神经系统疾病之外，但其在急性炎症性肺病中的参与情况在很大程度上仍不清楚。通过使用成熟的急性肺损伤（ALI）和脓毒症模型，我们证明了作为关键 NTF 的脑源性神经营养因子（BDNF）在肺上皮细胞中表达受损，且与炎症反应呈负相关。提高 BDNF 水平可减轻炎症性肺损伤，但这些效应在巨噬细胞缺失的小鼠中消失。体内和体外结果均显示 BDNF 能够抑制巨噬细胞炎症，进一步的蛋白质组学分析确定巨噬细胞表面的 TLR4 是 BDNF 通过直接结合产生拮抗作用的受体。BDNF 片段（aa 104-115）对 BDNF-TLR4 的相互作用至关重要，而相应的合成 BDNF 衍生十二肽（BDP-12）在体内外均保留了 TLR4 拮抗和抗炎作用，且不具备促增殖副作用。总之，我们的研究结果揭示了上皮来源的 BDNF 通过直接靶向 TLR4 预防巨噬细胞炎症，并突出了 BDP-12 作为急性炎症性疾病潜在治疗药物的价值。

### 第二部分 AI 大师评价

本研究揭示了脑源性神经营养因子（BDNF）在肺部免疫调节中的全新机制，证实其可作为内源性 TLR4 拮抗剂抑制巨噬细胞介导的过度炎症。研究通过蛋白质组学精准定位了 BDNF 与 TLR4 结合的关键序列，并开发出保留抗炎活性且规避促增殖风险的衍生肽 BDP-12。该成果不仅拓宽了神经营养因子的功能图谱，也为急性肺损伤和脓毒症等急性炎症性疾病提供了极具临床转化潜力的创新药物候选分子。

---

## 18. 基于血液的表观遗传不稳定性与人类衰老及疾病相关

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41690920)
**期刊：** Nature communications
**PMID：** 41690920
**DOI：** 10.1038/s41467-026-69430-z

### 第一部分 原文与翻译

**英文原标题：** Blood-based epigenetic instability linked to human aging and disease.

> **英文摘要：**
> The abundance, dynamics, and context-dependent heterogeneity of DNA methylation, where a pattern considered abnormal in one cell type may be normal in another, complicate the identification of early methylation changes that drive or signal disease development. This complexity can obscure early markers of increased disease risk, making it challenging to detect and intervene in disease processes at their inception. Here, we report 31,744 CpG loci exhibiting highly consistent methylation profiles in the blood of young, healthy individuals. We assess alterations at these epigenetically stable loci in 8,886 individuals across 29 diverse cohorts, including those with hematological cancers (n = 3159), cardiovascular complications (n = 2788), and healthy controls (n = 2939). Our findings reveal methylation pattern disruption in myeloid and lymphoid malignancies, correlating with clonal burden dynamics and mutation frequency throughout leukemia treatment. In non-cancer cohorts, we observe that methylation levels at epigenetically stable loci become increasingly variable with age, a shift linked to higher cardiovascular disease risk and lower survival rates. This study highlights DNA methylation instability as a blood-based biomarker for both hematological cancer and cardiovascular disease and uncovers a mechanistic link between methylation dynamics and the expansion of maladaptive hematopoietic clones.

> **中文摘要：**
> DNA甲基化的丰度、动态变化以及依赖于上下文的异质性（即在一种细胞类型中被认为异常的模式在另一种细胞类型中可能是正常的）使识别驱动或标志疾病发展的早期甲基化变化变得复杂。这种复杂性可能会掩盖疾病风险增加的早期标志物，从而给在疾病发生初期进行检测和干预带来挑战。在此，我们报告了31,744个在年轻健康个体血液中表现出高度一致甲基化图谱的CpG位点。我们在涵盖29个不同队列的8,886名个体中评估了这些表观遗传稳定位点的改变，其中包括血液系统癌症患者（n = 3159）、心血管并发症患者（n = 2788）和健康对照者（n = 2939）。我们的研究结果揭示了骨髓和淋巴恶性肿瘤中甲基化模式的破坏，这与白血病治疗过程中的克隆负荷动态和突变频率相关。在非癌症队列中，我们观察到表观遗传稳定位点的甲基化水平随着年龄的增长而变得越来越不稳定，这种转变与更高的心血管疾病风险和更低的生存率相关。本研究强调了DNA甲基化不稳定性可作为血液癌症和心血管疾病的血液生物标志物，并揭示了甲基化动态与适应不良造血克隆扩增之间的机制联系。

### 第二部分 AI 大师评价

本研究通过分析大规模人群队列，成功锁定了3万余个在健康个体中高度稳定的CpG位点，并提出了“表观遗传不稳定性”这一创新概念。研究不仅证明了这些位点的甲基化紊乱与血液系统恶性肿瘤的演进密切相关，还揭示了其在评估衰老及非癌症人群心血管风险中的独特价值。通过将分子异质性转化为可量化的生物标志物，该研究为疾病的早期预警和造血克隆演化的机制研究提供了重要的表观遗传学证据。

---

## 19. CycloPepper：一个用于预测环化结果并优化治疗性环肽合成的机器学习平台

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41690919)
**期刊：** Nature communications
**PMID：** 41690919
**DOI：** 10.1038/s41467-026-69441-w

### 第一部分 原文与翻译

**英文原标题：** CycloPepper: a machine learning platform for predicting cyclization outcomes and optimizing synthesis of therapeutic cyclopeptides.

> **英文摘要：**
> Cyclic peptides exhibit remarkable stability, membrane permeability, and binding affinity, positioning them as promising therapeutics. However, their synthesis, particularly on-resin head-to-tail cyclization, remains challenging, with cyclization site selection critically influencing yield. Here, we introduce a machine learning (ML) approach to predict cyclization outcomes, leveraging CycloBot, our fully automated cyclic peptide synthesis platform. Using this system, we generate a standardized dataset of 306 cyclic peptides (2-14 residues) and develop an ML model achieving an average prediction accuracy of 84%. Experimental validation with 74 random and therapeutic peptides showed an 86% prediction consistency. To facilitate practical use, we built CycloPepper, a user-friendly platform available through both web and software interfaces, enabling rapid cyclization site assessment. This tool effectively identified potential cyclization sites for disease-targeting peptides, including cancer biomarkers. Our work illustrates the potential of ML-assisted synthesis to streamline cyclic peptide synthesis and accelerate therapeutic discovery.

> **中文摘要：**
> 环肽表现出卓越的稳定性、膜渗透性和结合亲和力，使其成为具有前景的治疗药物。然而，它们的合成（特别是树脂上的头尾环化）仍然具有挑战性，其中环化位点的选择对产率有至关重要的影响。在此，我们介绍了一种预测环化结果的机器学习（ML）方法，该方法利用了我们的全自动环肽合成平台 CycloBot。通过该系统，我们生成了一个包含 306 种环肽（2-14 个残基）的标准数据集，并开发了一个平均预测准确率达到 84% 的机器学习模型。对 74 种随机肽和治疗肽的实验验证显示了 86% 的预测一致性。为了方便实际使用，我们构建了 CycloPepper，这是一个通过网页和软件界面提供的用户友好平台，能够进行快速的环化位点评估。该工具有效地识别了包括癌症生物标志物在内的疾病靶向肽的潜在环化位点。我们的工作展示了机器学习辅助合成在简化环肽合成和加速治疗药物发现方面的潜力。

### 第二部分 AI 大师评价

该研究针对环肽合成中“头尾环化”位点选择困难这一技术瓶颈，开发了基于机器学习的预测平台 CycloPepper。研究通过全自动合成平台 CycloBot 构建了高质量的标准数据集，实现了 84% 的预测准确率，并通过实验验证了其在治疗性肽段合成中的可靠性。该工作不仅为环肽药物的工业化合成提供了高效的评估工具，也展示了人工智能在复杂生物分子合成优化领域的应用潜力。

---

## 20. FOXJ1 通过调节微管动力学介导紫杉烷耐药

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41690905)
**期刊：** Nature communications
**PMID：** 41690905
**DOI：** 10.1038/s41467-026-69556-0

### 第一部分 原文与翻译

**英文原标题：** FOXJ1 mediates taxane resistance through regulation of microtubule dynamics.

> **英文摘要：**
> Docetaxel is the first-line chemotherapy for metastatic prostate cancer (PC), but clinically meaningful mechanisms of resistance remain to be established. Here we show, in an in vivo model of docetaxel resistant PC patient-derived xenografts, increased expression of genes that drive development of multiciliated cells including FOXJ1 and its effectors, many of which regulate microtubules (MTs). Mechanistically, FOXJ1 overexpression confers docetaxel resistance in vitro and in vivo, which is associated with decreased docetaxel-mediated MT bundling. Overexpression of a MT-associated FOXJ1-regulated gene (TPPP3) has similar effects. Conversely, FOXJ1 knockdown impairs basal MT function, enhances taxane binding to MTs, and increases docetaxel sensitivity. These results establish mechanistic causality between the FOXJ1 signaling axis, MT biology, and taxane resistance. Clinically, FOXJ1 gene amplification is increased in taxane-treated PC patients. Moreover, in the CHAARTED clinical trial of docetaxel combined with androgen deprivation for metastatic PC, higher baseline FOXJ1 is predictive of decreased survival in PC patients treated with docetaxel, further supporting clinical relevance. Together, these findings identify a previously unrecognized clinically impactful mechanism of taxane resistance whose exploitation could stratify patients who will not benefit from taxane treatment.

> **中文摘要：**
> 多西他赛是转移性前列腺癌（PC）的一线化疗方案，但临床上具有重要意义的耐药机制仍有待建立。在此，我们在多西他赛耐药的前列腺癌患者来源异种移植（PDX）体内模型中发现，驱动多纤毛细胞发育的基因（包括 FOXJ1 及其效应因子）表达增加，其中许多基因参与调节微管（MTs）。从机制上讲，FOXJ1 的过表达在体外和体内均可诱导多西他赛耐药性，这与多西他赛介导的微管成束减少有关。过表达受 FOXJ1 调控的微管相关基因（TPPP3）具有类似的效果。相反，敲降 FOXJ1 会损害基础微管功能，增强紫杉烷与微管的结合，并提高多西他赛敏感性。这些结果建立了 FOXJ1 信号轴、微管生物学与紫杉烷耐药之间的机械因果关系。临床上，接受紫杉烷治疗的前列腺癌患者中 FOXJ1 基因扩增频率增加。此外，在多西他赛联合雄激素剥夺治疗转移性前列腺癌的 CHAARTED 临床试验中，较高的基线 FOXJ1 水平预示着接受多西他赛治疗的患者生存期缩短，进一步支持了其临床相关性。总之，这些发现确定了一种先前未被公认的、具有临床影响力的紫杉烷耐药机制，利用该机制可以对无法从紫杉烷治疗中获益的患者进行精准分层。

### 第二部分 AI 大师评价

本研究通过整合 PDX 模型、机制实验以及 CHAARTED 临床试验数据，深入揭示了转录因子 FOXJ1 介导转移性前列腺癌对紫杉烷类药物耐药的核心机制。研究发现 FOXJ1 通过调节微管动力学和降低药物成束能力来诱导耐药，并证实了其关键效应因子 TPPP3 的协同作用。该研究不仅在生物学上建立了多纤毛发育基因与化疗耐药的新联系，更在临床层面验证了 FOXJ1 表达水平作为多西他赛治疗获益分层生物标志物的潜力，具有极高的临床转化价值。

---

## 21. 减重疗法与骨质疏松风险——作者回复

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41690748)
**期刊：** Lancet (London, England)
**PMID：** 41690748
**DOI：** 10.1016/S0140-6736(26)00105-4

### 第一部分 原文与翻译

**英文原标题：** Weight loss therapies and osteoporosis risk - Authors' reply.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

该文献属于医学期刊中的作者回复函，旨在针对“减重疗法与骨质疏松风险”相关研究中的疑问进行专业解答。作者通过此类沟通进一步阐述了减重干预对骨骼健康的潜在影响，并在学术讨论的背景下澄清了研究方法或结论的适用范围。尽管不具备正式的摘要结构，此类文献对于全面评估减重药物或手术的长期安全性，以及完善临床骨折风险防控策略具有重要的补充价值。

---

## 22. 更正：CoQ0 通过 ROS 介导的凋亡发挥抗 EMT 特性，其机制归因于 PI3K/AKT/NFκB/MMP-9 信号通路。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41689110)
**期刊：** Journal of experimental & clinical cancer research : CR
**PMID：** 41689110
**DOI：** 10.1186/s13046-026-03654-1

### 第一部分 原文与翻译

**英文原标题：** Correction: Anti-EMT properties of CoQ0 attributed to PI3K/AKT/NFKB/MMP-9 signaling pathway through ROS-mediated apoptosis.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

本文献为针对辅酶Q0（CoQ0）抗癌机制研究的一项勘误声明。原研究探讨了CoQ0如何通过活性氧（ROS）介导的凋亡途径抑制肿瘤细胞的上皮-间质转化（EMT），并详细阐述了其对PI3K/AKT/NFκB/MMP-9信号通路的下调作用。作为勘误文件，其核心价值在于修正原刊载论文中的数据或文字偏差，确保该项关于药理机制研究的准确性与科学严谨性。

---

## 23. ATRX缺失将富含G序列重复处的基因组不稳定与人α-珠蛋白表达失调联系起来

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41688464)
**期刊：** Nature communications
**PMID：** 41688464
**DOI：** 10.1038/s41467-026-69169-7

### 第一部分 原文与翻译

**英文原标题：** ATRX loss couples genome instability at a G-rich repeat to dysregulation of human alpha-globin expression.

> **英文摘要：**
> Germline mutations in the chromatin remodelling protein ATRX cause a severe developmental disorder associated with α-thalassemia. In addition, ATRX is amongst the twenty genes most frequently mutated in cancer. How ATRX mutations alter gene expression remains unclear. Using the α-globin locus as a model, here we show that ATRX deficiency downregulates α-globin in a subset of cells exhibiting DNA damage. A G-rich repeat at the α-globin locus serves as a potential site of G-quadruplex formation and DNA damage. ATRX binds this repeat co-transcriptionally, and its loss increases R-loop accumulation at this site, leading to local DNA damage and transcriptional disruption in cis. Deletion of this repeat abolishes this effect, while targeted DNA damage reinstates it. These findings reveal a mechanism linking ATRX's role in genome stability to transcriptional regulation and uncover a molecular basis of human genetic disease mediated via a distal G-rich repeat.

> **中文摘要：**
> 染色质重塑蛋白ATRX的生殖细胞突变会导致与α-地中海贫血相关的严重发育障碍。此外，ATRX是癌症中最常发生突变的20个基因之一。ATRX突变如何改变基因表达仍不清楚。以α-珠蛋白位点为模型，我们在此表明，ATRX缺乏会在表现出DNA损伤的一部分细胞中下调α-珠蛋白。α-珠蛋白位点处的一个富含G的重复序列是G-四联体形成和DNA损伤的潜在位点。ATRX在转录过程中结合该重复序列，其缺失会增加该位点的R-环积累，导致局部的DNA损伤和顺式转录中断。缺失该重复序列可消除此效应，而靶向DNA损伤则可使其恢复。这些发现揭示了一种将ATRX在基因组稳定性中的作用与转录调节联系起来的机制，并发现了由远端富含G的重复序列介导的人类遗传疾病的分子基础。

### 第二部分 AI 大师评价

本文深入探讨了染色质重塑蛋白ATRX缺失导致α-地中海贫血的分子机制。研究通过α-珠蛋白位点模型发现，ATRX通过结合富含G的重复序列来防止R-环积累，从而维持基因组稳定。当ATRX缺失时，特定位点的DNA损伤会导致基因转录的顺式中断，这一发现不仅揭示了ATRX在转录调控与基因组稳定性之间的桥梁作用，也为理解非编码重复序列在遗传病中的作用提供了关键证据。

---

## 24. USP30介导的己糖激酶2去泛素化控制葡萄糖代谢归宿及肿瘤进展

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41688443)
**期刊：** Cell death & disease
**PMID：** 41688443
**DOI：** 10.1038/s41419-026-08459-w

### 第一部分 原文与翻译

**英文原标题：** USP30-mediated Deubiquitination of Hexokinase 2 controls the metabolic fate of glucose and tumor progression.

> **英文摘要：**
> The mitochondria-localized deubiquitinase USP30 regulates mitophagy and mitochondrial homeostasis, playing a significant role in the progression of neurodegenerative diseases. However, its role in cancer remains poorly understood. Through metabolism-related gene set enrichment analysis, we identified USP30 as a key modulator of glucose metabolism in cancer cells. Utilizing quantitative proteomic and ubiquitinomic approaches coupled with co-immunoprecipitation assays, we elucidated that USP30 regulates glycolysis by interacting with hexokinase HK1 and HK2, a process dependent on its enzymatic activity. USP30 modulates the ubiquitination profile of HK1 and HK2 by preferentially removing atypical ubiquitin chains, thereby enhancing their stability, mitochondrial localization, VDAC1 binding and hexokinase activity. Lysine 144 emerges as a critical regulatory site for USP30-mediated deubiquitination of HK2. Mutation of K144 enhances HK2 stability, increases its mitochondrial localization and binding to VDAC1, and significantly augments hexokinase activity. Furthermore, the HK2 K144 mutation markedly enhances tumor cell glycolysis, fostering increased proliferation and migration both in vitro and in vivo. These findings underscore USP30 as a novel regulator of glycolysis in cancer cells via modulation of HK2 ubiquitination dynamics, suggesting its potential as a therapeutic target in cancer metabolism.

> **中文摘要：**
> 线粒体定位的去泛素化酶 USP30 调节线粒体自噬和线粒体稳态，在神经退行性疾病的进展中发挥着重要作用。然而，其在癌症中的作用仍知之甚少。通过代谢相关的基因集富集分析（GSEA），我们确定了 USP30 是癌细胞葡萄糖代谢的关键调节因子。利用定量蛋白质组学和泛素组学方法结合共免疫沉淀实验，我们阐明了 USP30 通过与己糖激酶 HK1 和 HK2 相互作用来调节糖酵解，这一过程依赖于其酶活性。USP30 通过优先移除不典型泛素链来调节 HK1 和 HK2 的泛素化谱，从而增强它们的稳定性、线粒体定位、与 VDAC1 的结合以及己糖激酶活性。赖氨酸 144（K144）成为 USP30 介导的 HK2 去泛素化的关键调节位点。K144 突变增强了 HK2 的稳定性，增加了其线粒体定位以及与 VDAC1 的结合，并显著增强了己糖激酶活性。此外，HK2 K144 突变在体外和体内均显著增强了肿瘤细胞的糖酵解，促进了增殖和迁移的增加。这些发现强调了 USP30 通过调节 HK2 泛素化动力学成为癌细胞糖酵解的新型调节因子，表明其作为癌症代谢治疗靶点的潜力。

### 第二部分 AI 大师评价

本研究深入探讨了去泛素化酶 USP30 在癌症代谢重塑中的关键角色，揭示了其通过稳定关键限速酶 HK2 驱动糖酵解的分子机制。研究采用定量泛素组学等前沿技术，精准锁定了 HK2 的 K144 位点为去泛素化的核心调节位点，并阐明了该修饰对 HK2 线粒体定位及酶活性的调控逻辑。研究结果在体内外实验中均得到了验证，不仅拓展了 USP30 的病理生理功能边界，也为靶向肿瘤能量代谢途径的药物研发提供了极具潜力的候选靶点。

---

## 25. cfGWAS 揭示游离 DNA 末端基序的遗传基础

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41688428)
**期刊：** Nature communications
**PMID：** 41688428
**DOI：** 10.1038/s41467-025-67940-w

### 第一部分 原文与翻译

**英文原标题：** cfGWAS reveal genetic basis of cell-free DNA end motifs.

> **英文摘要：**
> Cell-free DNA (cfDNA) consists of degraded DNA fragments released into body fluids. Its genetic and pathological information makes it useful for prenatal testing and early tumor detection. However, the mechanisms behind cfDNA biology are largely unknown. In this study, for the first time, we conduct a genome-wide association study (GWAS) to explore the genetic basis of cfDNA end motif frequencies, termed cfGWAS, in 28,016 pregnant women. We identify 15 study-wide significant loci, including the well-known cfDNA-related genes DFFB and DNASE1L3, as well as novel genes potentially involved in cfDNA biology, such as PANX1 and DNASE1L1. The findings are further verified through three independent GWAS studies and experimental validation in knockout mice and cell lines. Subsequent analyses reveal strong causal relationships of leukocytes, especially neutrophils, with cfDNA features. In summary, we introduce the cfGWAS, revealing the genetic basis of cfDNA biology on a genome-wide scale. Novel knowledge uncovered by this study promises to revolutionize liquid biopsy technology and lead to potential new drugs targeting certain diseases. Given that millions of cfDNA whole genome sequencing data have been generated from clinical testing, the potential of this paradigm is enormous.

> **中文摘要：**
> 游离 DNA（cfDNA）由释放到体液中的降解 DNA 片段组成。其遗传和病理信息使其在产前检测和早期肿瘤检测中具有重要价值。然而，cfDNA 生物学背后的机制在很大程度上仍是未知的。在本研究中，我们首次在 28,016 名孕妇中开展了全基因组关联研究（GWAS），旨在探索 cfDNA 末端基序频率的遗传基础，并将其命名为 cfGWAS。我们鉴定了 15 个全研究显著性位点，包括著名的 cfDNA 相关基因 DFFB 和 DNASE1L3，以及可能参与 cfDNA 生物学的新基因，如 PANX1 和 DNASE1L1。这些发现通过三个独立的 GWAS 研究以及在敲除小鼠和细胞系中的实验验证得到了进一步证实。随后的分析揭示了白细胞（尤其是中性粒细胞）与 cfDNA 特征之间存在强有力的因果关系。总之，我们引入了 cfGWAS，在全基因组尺度上揭示了 cfDNA 生物学的遗传基础。本研究揭示的新知识有望彻底改变液体活检技术，并为针对某些疾病的潜在新药开发提供指导。鉴于临床检测已产生了数百万份 cfDNA 全基因组测序数据，这一范式的潜力是巨大的。

### 第二部分 AI 大师评价

该研究通过对28,016名孕妇的大规模队列进行全基因组关联分析，首次定义并实施了cfGWAS，旨在揭示驱动cfDNA末端基序特征的遗传因子。研究不仅验证了DNASE1L3等已知关键基因，还发现了PANX1和DNASE1L1等新型候选基因，并通过跨物种实验和细胞系验证了其生物学功能。通过孟德尔随机化等分析，研究强调了中性粒细胞在cfDNA碎片化过程中的核心作用，为优化基于cfDNA的液体活检精度和探索相关疾病治疗靶点提供了坚实的遗传学证据。

---

## 26. 重塑黑色素瘤细胞命运：TRPM8 调节剂触发凋亡并增强 NK 细胞的细胞毒性

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41688418)
**期刊：** Cell death & disease
**PMID：** 41688418
**DOI：** 10.1038/s41419-026-08469-8

### 第一部分 原文与翻译

**英文原标题：** Rewiring melanoma cell fate: TRPM8 modulators trigger apoptosis and boost NK cell cytotoxicity.

> **英文摘要：**
> Metastatic melanoma is an aggressive malignancy with limited long-term treatment success due to therapeutic resistance and immune evasion. The transient receptor potential melastatin 8 (TRPM8) ion channel is overexpressed in melanoma but its role as therapeutic target remains unexplored. We investigated the anti-tumor effects of novel TRPM8 modulators in metastatic melanoma cells using viability assays, apoptosis markers, mitochondrial function analyses, reactive oxygen species (ROS) measurements and gene silencing. Their functional impact was further assessed in 3D melanoma organoids, clonogenic survival assays, and natural killer (NK) cell co-culture systems. TRPM8 is significantly overexpressed in metastatic melanoma, as compared with the normal counterparts. Its pharmacological inhibition with novel modulators selectively induces calcium-independent mitochondrial apoptosis characterized by ROS accumulation, mitochondrial membrane depolarization, cytochrome c release, and caspase-3 activation. This process involves activation of the ATM/p53 pathway and upregulation of pro-apoptotic proteins. Additionally, TRPM8 modulators increase expression of the NK cell-activating ligand ULBP1, enhancing melanoma susceptibility to NK-mediated cytotoxicity. Our study identifies TRPM8 as a promising biomarker in melanoma. Its targeting triggers mitochondrial cell death and simultaneously boosts NK cell recognition via ULBP1/NKG2D engagement. TRPM8 targeting in combination with immunotherapy might be, hence, further explored in clinical setting of advanced melanoma.

> **中文摘要：**
> 转移性黑色素瘤是一种侵袭性恶性肿瘤，由于治疗耐药和免疫逃逸，长期治疗成功率有限。瞬时受体电位美司他丁 8 (TRPM8) 离子通道在黑色素瘤中过度表达，但其作为治疗靶点的作用尚待探索。我们利用活力测定、凋亡标记物、线粒体功能分析、活性氧 (ROS) 测量和基因沉默技术，研究了新型 TRPM8 调节剂在转移性黑色素瘤细胞中的抗肿瘤作用。通过 3D 黑色素瘤类器官、克隆形成生存实验和自然杀伤 (NK) 细胞共培养系统进一步评估了它们的功能影响。与正常对应物相比，TRPM8 在转移性黑色素瘤中显著高表达。使用新型调节剂对其进行药理抑制，可选择性地诱导非钙依赖性的线粒体凋亡，其特征是 ROS 积累、线粒体膜去极化、细胞色素 c 释放和 caspase-3 激活。这一过程涉及 ATM/p53 通路的激活和促凋亡蛋白的上调。此外，TRPM8 调节剂增加了 NK 细胞激活配体 ULBP1 的表达，增强了黑色素瘤对 NK 介导的细胞毒性的敏感性。我们的研究确定了 TRPM8 是黑色素瘤中一个极具前景的生物标志物。靶向 TRPM8 可触发线粒体细胞死亡，并同时通过 ULBP1/NKG2D 结合增强 NK 细胞的识别。因此，在晚期黑色素瘤的临床背景下，可以进一步探索 TRPM8 靶向结合免疫疗法的方案。

### 第二部分 AI 大师评价

该研究深入探讨了 TRPM8 离子通道在转移性黑色素瘤中的作用，揭示了其作为新型治疗靶点的潜力。作者通过整合分子生物学、3D 类器官及免疫共培养等多种模型，证实了 TRPM8 调节剂能通过激活 ATM/p53 通路诱导线粒体凋亡。研究的创新性在于发现靶向 TRPM8 不仅能直接诱导肿瘤细胞死亡，还能通过上调 ULBP1 增强 NK 细胞的免疫识别，为晚期黑色素瘤的联合免疫治疗提供了坚实的实验依据。

---

## 27. 他汀类药物说明书中所列不良反应的评估：一项双盲随机对照试验的元分析

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41655587)
**期刊：** Lancet (London, England)
**PMID：** 41655587
**DOI：** 10.1016/S0140-6736(25)01578-8

### 第一部分 原文与翻译

**英文原标题：** Assessment of adverse effects attributed to statin therapy in product labels: a meta-analysis of double-blind randomised controlled trials.

> **英文摘要：**
> BACKGROUND: Statin product labels (eg, Summaries of Product Characteristics [SmPCs]) list certain adverse outcomes as potential treatment-related effects based mainly on non-randomised and non-blinded studies, which might be subject to bias. We aimed to assess the evidence for such undesirable effects more reliably through a meta-analysis of individual participant data from large double-blind trials of statin therapy. METHODS: In this meta-analysis of individual participant-level data from double-blind randomised controlled trials, we generated a list of all undesirable effect terms listed in statin SmPCs by searching an electronic medicines compendium for five statins (atorvastatin, fluvastatin, pravastatin, rosuvastatin, and simvastatin). Randomised trials were eligible for meta-analysis of these effects if they involved at least 1000 participants, had a scheduled treatment period of at least 2 years, and involved a double-blind comparison of statin versus placebo or of a more intensive versus a less intensive statin regimen. Event rate ratios (RRs) and 95% CIs were calculated with statistical significance assessed after controlling the false discovery rate (FDR) at 5%. FINDINGS: 19 trials compared statin versus placebo (123 940 participants, median follow-up 4·5 years [IQR 3·1-5·4]). In addition to previously reported effects on muscle outcomes and diabetes, only four of 66 further undesirable outcomes that had been attributed to statins were FDR significant: abnormal liver transaminases (783 participants [0·30% per annum] allocated statin vs 556 [0·22% per annum] allocated placebo, RR 1·41 [95% CI 1·26-1·57]) and other liver function test abnormalities (651 participants [0·25% per annum] allocated statin vs 518 [0·20% per annum] allocated placebo, RR 1·26 [1·12-1·41]; absolute annual excess of 0·13% for combined liver function test abnormality), urinary composition alteration (556 [0·21% per annum] allocated statin vs 472 [0·18% per annum] allocated placebo, RR 1·18 [1·04-1·33]), and oedema (3495 [1·38% per annum] allocated statin vs 3299 [1·31% per annum] allocated placebo, RR 1·07 [1·02-1·12]). Analysis of the four trials of more intensive versus less intensive statin regimens also found significant excesses for abnormal liver transaminases and other liver function test abnormalities (supporting a dose-dependent effect), but no significant excess was found for urinary composition alteration or oedema. INTERPRETATION: Adverse event data from blinded randomised trials do not support causal relationships between statin therapy and most of the conditions (including cognitive impairment, depression, sleep disturbance, and peripheral neuropathy) listed in product labels as potential undesirable effects. In light of these findings, such labelling and other official sources of health information should be revised so that patients and their doctors can make appropriately informed decisions regarding statin therapy. FUNDING: British Heart Foundation, UK Medical Research Council, and Australian National Health and Medical Research Council.

> **中文摘要：**
> 背景：他汀类药物产品说明书（如产品特性概要 [SmPCs]）将某些不良结局列为潜在的治疗相关效应，这主要基于非随机和非盲法研究，而此类研究可能存在偏倚。本研究旨在通过对大型他汀治疗双盲试验的个体参与者数据进行元分析，更可靠地评估这些不良效应的证据。方法：在这项针对双盲随机对照试验个体受试者层面数据的元分析中，我们通过检索电子药物指南中五种他汀类药物（阿托伐他汀、氟伐他汀、普伐他汀、瑞舒伐他汀和辛伐他汀）的信息，生成了说明书中列出的所有不良效应术语清单。入选元分析的随机试验需满足：参与者至少1000人，预定治疗期至少2年，且包含他汀与安慰剂或更强化与较弱化他汀方案的双盲对照。计算事件率比（RRs）及其95% CI，并在错误发现率（FDR）控制在5%后评估统计学显著性。结果：19项试验对比了他汀与安慰剂（123,940名参与者，中位随访4.5年 [IQR 3.1-5.4]）。除了先前报道过的对肌肉结局和糖尿病的影响外，在归因于他汀类药物的另外66项不良结局中，仅有4项在FDR校正后具有显著性：肝转氨酶异常（他汀组783人 [年发生率0.30%] vs 安慰剂组556人 [年发生率0.22%]，RR 1.41 [95% CI 1.26-1.57]）和其他肝功能检查异常（他汀组651人 [年发生率0.25%] vs 安慰剂组518人 [年发生率0.20%]，RR 1.26 [1.12-1.41]；合并肝功能异常的绝对年额外发生率为0.13%）、尿液成分改变（他汀组556人 [年发生率0.21%] vs 安慰剂组472人 [年发生率0.18%]，RR 1.18 [1.04-1.33]）以及水肿（他汀组3495人 [年发生率1.38%] vs 安慰剂组3299人 [年发生率1.31%]，RR 1.07 [1.02-1.12]）。对4项更强化对比较弱化他汀方案试验的分析也发现，肝转氨酶异常和其他肝功能检查异常显著增加（支持剂量依赖效应），但未发现尿液成分改变或水肿显著增加。解释：来自双盲随机试验的不良事件数据并不支持他汀类药物治疗与产品说明书中列出的大多数潜在不良效应（包括认知功能障碍、抑郁、睡眠障碍和周围神经病变）之间存在因果关系。鉴于这些发现，应当修订此类说明书及其他官方健康信息来源，以便患者及其医生能够就他汀类药物治疗做出恰当的知情决策。资助：英国心脏基金会、英国医学研究理事会和澳大利亚国家健康与医学研究理事会。

### 第二部分 AI 大师评价

本研究是一项基于大规模双盲随机对照试验个体参与者数据（IPD）的高质量元分析，旨在验证他汀类药物说明书中所列不良反应的真实因果关系。研究发现，在66项被标注的潜在不良反应中，除已知的肌肉损害和糖尿病风险外，仅肝功能指标、尿液成分改变及水肿等极少数项与他汀使用存在显著统计学关联，而认知障碍、抑郁及睡眠障碍等大多数所谓副作用并未在严谨的临床试验中得到证实。该研究结果挑战了现行的药品说明书标注标准，为减少医疗过程中的“反安慰剂效应”提供了重要科学依据，强调了根据高质量证据修订药品标签以促进医患科学决策的紧迫性。

---

速递结束，祝您工作愉快！